# Adenosine vs. Diltiazem

Study · id `cardio:ct-nct07456423` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07456423](<https://clinicaltrials.gov/study/NCT07456423>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07456423

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT07456423. Randomized; single masking; primary purpose treatment. Start 2024-07-01 (actual); primary completion 2025-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT07456423, source copy `cardio:ctgov-nct07456423-2026-03-06`, retrieved 2026-10-26)
- Started: 2024-07-01 (actual) (ClinicalTrials.gov record NCT07456423, source copy `cardio:ctgov-nct07456423-2026-03-06`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT07456423, source copy `cardio:ctgov-nct07456423-2026-03-06`, retrieved 2026-10-26)
- Completion: 2025-08-30 (actual) (ClinicalTrials.gov record NCT07456423, source copy `cardio:ctgov-nct07456423-2026-03-06`, retrieved 2026-10-26)
- Countries: Türkiye (ClinicalTrials.gov record NCT07456423, source copy `cardio:ctgov-nct07456423-2026-03-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07456423-2026-03-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Adenosine vs. Diltiazem
- Acronym: AVNRTstdy
- Condition: Supraventricular Tachycardia (SVT)
- Condition: Atrioventricular Nodal Re Entrant Tachycardia
- Intervention (Drug): Adenosine intravenous
- Intervention (Drug): Diltiazem intravenous
- Lead sponsor: Haseki Training and Research Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Supraventricular tachycardia (`cardio:supraventricular-tachycardia`)

## Provenance

Content hash: 351395e41e59f2a465aa7b710f20fdc7aa79e5a6440c1a22b867f67cc2b68ed0
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
